RNA Therapeutics Market by Modality (mRNA, siRNA, Antisense Oligonucleotides, Self-Amplifying RNA, Others (tRNA therapeutics, circular RNA (circRNA), RNA aptamers, microRNA mimics and inhibitors, and saRNA-adjacent modalities)), by Application (Infectious Disease Vaccines, Oncology, Rare & Genetic Disease, Cardiometabolic Disease, Others (Neurological disease, ophthalmic disease, respiratory disease, autoimmune disease, and regenerative medicine)), by Delivery Technology (Lipid Nanoparticles, Viral Vectors, Polymer-Based Delivery, Others (Lipid-polymer hybrids, exosome-based delivery, GalNAc conjugates, peptide-based delivery, and inorganic nanoparticles)), by End User (Biopharmaceutical Companies, CROs/CDMOs, Academic & Research Institutes), and by Region — Global Industry Perspective, Comprehensive Analysis, and Forecast 2026–2035
St. Catharines, Ontario, 7 Nov 2026 — Vectomat Insights has published a new report titled ‘RNA Therapeutics Market by Modality, Application, Delivery Technology, End User, and Region — Global Industry Perspective, Comprehensive Analysis, and Forecast 2026–2035.’ The Global RNA Therapeutics market was valued at USD 11,864.3 Mn in 2025 and is projected to reach USD 38,424.6 Mn by 2035, growing at a CAGR of 12.47% during the forecast period 2026–2035, according to Vectomat Insights.
mRNA still earns the largest slice at 45.9% of 2025 revenue, but the momentum has moved to gene-silencing drugs: Alnylam's Amvuttra won FDA approval in ATTR cardiomyopathy in March 2025, and North America holds 39.0% of global sales on the back of five US RNA-medicine approvals in 2025.
The Global RNA Therapeutics market was valued at USD 11,864.3 Mn in 2025 and will reach USD 38,424.6 Mn by 2035 at a 12.47% CAGR, according to Vectomat Insights. mRNA leads modalities with a 45.9% share, North America holds 39.0% of revenue, and self-amplifying RNA is the fastest-growing modality at 18.6% a year.
Key Insights Snapshot
| Metric | Value |
|---|---|
| Report Title | Global RNA Therapeutics Market Size, Share, Growth & Forecast By Modality, Application, Delivery Technology, and End User, 2026–2035 |
| Base Year Market Size | USD 11,864.3 Mn (2025) |
| Forecast Market Size | USD 38,424.6 Mn (2035) |
| CAGR | 12.47% |
| Forecast Period | 2026–2035 |
| Dominant Region | North America (39.0%) |
| Fastest-Growing Region | Asia Pacific |
| Dominant Segment | mRNA (45.9%) |
| Dominant Application | Infectious Disease Vaccines |
| Report Format | |
| Publisher | Vectomat Insights |
What Pharmaceutical Leaders Need to Know About the RNA Therapeutics Market
Pharma R&D Heads: Gene silencing has stopped being a rare-disease bet. Amvuttra's March 2025 ATTR-CM approval and Arrowhead's Redemplo launch in November 2025 show siRNA can win large cardiometabolic labels, and siRNA already earns 30.0% of category revenue. Pipelines without an RNA-silencing asset in cardiometabolic disease risk being outbid for partners.
Chief Medical Officers: Twice-yearly or quarterly RNA injections are changing adherence economics in chronic care. With cardiometabolic RNA revenue compounding at 16.96% a year, formulary and clinic workflows built around daily pills will need rework within this budget cycle.
Manufacturing & CDMO Executives: Outsourcing is the fastest-growing spend line: CROs/CDMOs grow at 18.99% a year to USD 17,552.8 Mn by 2035, overtaking in-house sponsor spend. Samsung Biologics and Lonza are already adding mRNA and LNP capacity; providers that can't fill GalNAc-siRNA or LNP lots at scale will lose tenders.
Healthcare Investors: Deal value is concentrating in RNA platforms, not single assets. Novartis paid about USD 12 Bn for Avidity, AbbVie up to USD 2.1 Bn for Capstan's in vivo CAR-T, and BioNTech took CureVac, so valuations for validated delivery chemistry are running ahead of the wider biotech index.
Regulatory & Market Access Directors: US policy now splits the category in two. HHS cancelled 22 BARDA mRNA projects worth about USD 500 Mn in August 2025, while FDA cleared five RNA medicines that year. Vaccine portfolios need ex-US launch sequencing, while silencing drugs keep a clear US path.

What Is the RNA Therapeutics Market?
RNA Therapeutics Market refers to medicines and vaccines that use ribonucleic acid to instruct, silence or edit how cells make proteins. The case for paying attention now is simple: revenue no longer depends on pandemic vaccines. Alnylam crossed roughly USD 3 Bn in 2025 sales on its TTR franchise, Ionis and Arrowhead launched their own drugs, and Novartis paid about USD 12 Bn for Avidity's RNA platform. The category spans mRNA, siRNA, antisense oligonucleotides and self-amplifying RNA. Vectomat Insights sizes it at USD 11,864.3 Mn in 2025, climbing to USD 38,424.6 Mn by 2035.
How Is the RNA Therapeutics Market Segmented?
mRNA owns 45.9% of 2025 revenue, about USD 5,440.4 Mn, but it's no longer setting the pace. Self-amplifying RNA is the fastest-growing modality at 18.6% a year, helped by the EU's approval of CSL and Arcturus' Kostaive in February 2025. By application, infectious disease vaccines still lead at 37.9%, though cardiometabolic disease grows fastest at 16.96% as twice-yearly drugs like Leqvio reach primary care. Lipid nanoparticles carry 55.7% of revenue. Biopharmaceutical companies account for 60.0% of spend, yet CROs and CDMOs are expanding at 18.99% a year.
This report segments the RNA Therapeutics market as follows:
- By Modality: mRNA, siRNA, Antisense Oligonucleotides, Self-Amplifying RNA, Others (tRNA therapeutics, circular RNA (circRNA), RNA aptamers, microRNA mimics and inhibitors, and saRNA-adjacent modalities)
- By Application: Infectious Disease Vaccines, Oncology, Rare & Genetic Disease, Cardiometabolic Disease, Others (Neurological disease, ophthalmic disease, respiratory disease, autoimmune disease, and regenerative medicine)
- By Delivery Technology: Lipid Nanoparticles, Viral Vectors, Polymer-Based Delivery, Others (Lipid-polymer hybrids, exosome-based delivery, GalNAc conjugates, peptide-based delivery, and inorganic nanoparticles)
- By End User: Biopharmaceutical Companies, CROs/CDMOs, Academic & Research Institutes
- By Region: North America, Europe, Asia Pacific, Latin America, The Middle East, Africa

Which Region Leads the RNA Therapeutics Market?
North America is the clear leader. It took 39.0% of 2025 revenue, about USD 4,627.1 Mn, and the United States alone was worth USD 3,701.7 Mn. Five FDA approvals of RNA medicines in 2025 kept US demand moving even as federal support for mRNA vaccines fell away. Europe is next at 27.0%, anchored by Germany's USD 897.0 Mn market and BioNTech's purchase of CureVac. Asia Pacific holds 23.0% and is the fastest-growing region, with South Korea compounding at 14.7% a year on state-backed mRNA programmes. Latin America has 5.0%, the Middle East 3.1% and Africa 3.0%.

Key Factors Propelling the RNA Therapeutics Market
RNAi Expansion Into Common Disease — Gene silencing has broken out of rare disease. Amvuttra's March 2025 approval in ATTR cardiomyopathy helped lift Alnylam's TTR revenue 151% in 2025.
Validated Delivery Chemistry — GalNAc conjugates and lipid nanoparticles now work reliably at commercial scale, cutting the technical risk that once scared off investors.
Platform M&A by Big Pharma — Large drugmakers are buying RNA platforms outright. Novartis closed its roughly USD 12 Bn Avidity deal in February 2026.
mRNA Cancer Vaccines Reach Phase 3 — Personalised mRNA cancer vaccines now have Phase 3 proof. Merck and Moderna's intismeran met its melanoma endpoint in August 2026.
Acquiring Avidity is a defining move that puts Novartis on course to become a leader in neuromuscular diseases, built on RNA-targeting medicines.
Key Headwinds Facing the RNA Therapeutics Market
US Policy Shift Against mRNA Vaccines — Washington has turned cool on mRNA vaccines: HHS cancelled 22 BARDA projects worth about USD 500 Mn in August 2025.
Post-Pandemic Revenue Collapse — COVID-19 revenue keeps shrinking. Moderna's 2025 product sales fell 42% to USD 1.82 Bn.
High Prices and Reimbursement Limits — Six-figure annual prices for silencing drugs meet tougher payers, especially in Europe.
Even with these headwinds, the market still grows from USD 11,864.3 Mn in 2025 to USD 38,424.6 Mn by 2035.
What Industry Leaders Are Saying About the RNA Therapeutics Market
Moderna will not start new late-stage infectious-disease vaccine trials while the policy backlash against vaccines in the United States shrinks the market for them.
After reviewing the science, we concluded that these mRNA vaccines do not protect well against upper respiratory infections such as COVID-19 and flu, so BARDA is moving its funding to other platforms.
Vaccines are a national security issue.
Report Segmentation & Scope
| Vectomat Insights | Market & Reports — Report Segmentation & Scope | |
|---|---|
| Scope Included in the Study | |
| By Modality |
|
| By Application |
|
| By Delivery Technology |
|
| By End User |
|
| Regional Analysis | |
| North America | The U.S., Canada, Mexico |
| Europe | Germany, France, U.K., Italy, Spain, Russia, BENELUX, Sweden, Denmark, Poland, Austria, Rest of Europe |
| Asia Pacific | China, Japan, India, South Korea, Australia, Thailand, Indonesia, Vietnam, Malaysia, Philippines, Taiwan, Rest of Asia Pacific |
| Latin America | Brazil, Argentina, Colombia, Chile, Peru, Rest of Latin America |
| The Middle East | GCC (Saudi Arabia, UAE, Qatar, Kuwait, Bahrain, Oman), Israel, Turkey, Iran, Rest of Middle East |
| Africa | South Africa, Egypt, Nigeria, Algeria, Morocco, Rest of Africa |
| Note: The scope can be further tailored as per your specific requirement. Contact sales@vectomatinsights.com | |
Who Are the Leading Companies in the RNA Therapeutics Market?
Key players operating in the Global RNA Therapeutics market include Alnylam Pharmaceuticals (U.S.), Ionis Pharmaceuticals (U.S.), Arrowhead Pharmaceuticals (U.S.), Novartis (Switzerland), Moderna (U.S.), BioNTech (Germany), Pfizer (U.S.), Biogen (U.S.), Sarepta Therapeutics (U.S.), CSL (Australia), Gennova Biopharmaceuticals (India), Samsung Biologics (South Korea), Maravai LifeSciences (U.S.), Aldevron (U.S.) and Lonza (Switzerland), among others. The power has shifted. Vaccine makers built the category, but silencing specialists now set the pace: Alnylam turned profitable in 2025 on roughly USD 3 Bn of revenue, while Moderna's product sales fell 42%. Big pharma is buying in rather than building, and suppliers of capping reagents and LNP capacity are quietly winning both ways.
RNA Therapeutics Market: Latest Industry Moves
March 2025 — Alnylam Pharmaceuticals: FDA approved Amvuttra (vutrisiran) for ATTR cardiomyopathy, the first RNAi therapeutic shown to reduce cardiovascular death and hospitalisation.
June 2025 — AbbVie: AbbVie agreed to acquire Capstan Therapeutics for up to USD 2.1 Bn, gaining an in vivo CAR-T platform built on targeted LNP-mRNA.
December 2025 — BioNTech: BioNTech closed its acquisition of CureVac, including the subsequent offering period, combining Germany's two leading mRNA developers.
February 2026 — Novartis: Novartis completed its roughly USD 12 Bn acquisition of Avidity Biosciences and its antibody-oligonucleotide conjugates for neuromuscular disease.
March 2026 — Moderna: Moderna agreed a USD 2.25 Bn global settlement of lipid nanoparticle patent litigation with Arbutus Biopharma and Genevant Sciences.
August 2026 — Moderna: With Merck, Moderna reported that the Phase 3 INTerpath-001 trial of intismeran autogene plus Keytruda met its recurrence-free survival endpoint in resected melanoma.
Frequently Asked Questions
How big is the RNA therapeutics market?
The global RNA therapeutics market was worth USD 11,864.3 Mn in 2025 and is set to reach USD 38,424.6 Mn by 2035, a compound annual growth rate of 12.47% over 2026–2035. Growth now comes mainly from gene-silencing drugs and oncology rather than COVID-19 vaccines, which peaked earlier in the decade. mRNA remains the largest modality, but siRNA and antisense drugs are gaining share every year, according to Vectomat Insights.
Which RNA modality has the largest share?
mRNA holds the largest share, at 45.9% of 2025 revenue or USD 5,440.4 Mn, because of established vaccines such as Comirnaty, Spikevax and the newer mNEXSPIKE and mRESVIA. siRNA ranks second at 30.0%, followed by antisense oligonucleotides at 12.1%. mRNA's share is forecast to fall to 37.5% by 2035 as silencing drugs and self-amplifying RNA grow faster, according to Vectomat Insights.
Which region leads the RNA therapeutics market?
North America leads with 39.0% of global revenue, about USD 4,627.1 Mn in 2025, and the United States alone accounts for USD 3,701.7 Mn. The region benefits from fast FDA approvals, with five RNA medicines cleared in 2025, and high specialty-drug prices. Europe follows at 27.0%, while Asia Pacific, at 23.0%, is the fastest-growing region over the forecast period, according to Vectomat Insights.
What is driving growth in RNA therapeutics?
Four forces are pushing the market forward: siRNA drugs moving into common diseases such as ATTR cardiomyopathy and high triglycerides, reliable delivery through GalNAc conjugates and lipid nanoparticles, big-pharma acquisitions such as Novartis' roughly USD 12 Bn purchase of Avidity, and the first Phase 3 success for a personalised mRNA cancer vaccine in August 2026. Together they offset falling COVID-19 vaccine revenue, according to Vectomat Insights.
Who are the leading companies in RNA therapeutics?
Leading companies include Alnylam Pharmaceuticals, Ionis Pharmaceuticals, Arrowhead Pharmaceuticals, Novartis, Moderna, BioNTech, Pfizer, Biogen, Sarepta Therapeutics and CSL, supported by Gennova Biopharmaceuticals and suppliers such as Samsung Biologics, Maravai LifeSciences, Aldevron and Lonza. Alnylam is currently the largest pure-play silencing company, with roughly USD 3 Bn of 2025 revenue, while Moderna and BioNTech lead in mRNA, according to Vectomat Insights.
What are the main risks for the RNA therapeutics market?
The biggest risk is US vaccine policy: HHS cancelled 22 BARDA mRNA projects worth about USD 500 Mn in August 2025, and COVID-19 vaccine demand has fallen sharply. Shrinking pandemic revenue at Moderna and BioNTech limits new investment, and high prices for silencing drugs face payer resistance in Europe. Cold-chain needs also restrict reach in lower-income regions, according to Vectomat Insights.
Access the Complete RNA Therapeutics Market Report
300+ pages | Global coverage | PDF | 2026
Contact: sales@vectomatinsights.com
About Vectomat Insights
Vectomat Insights is an independent market research firm. Our analysts build every market model in-house, from company revenues, government and regulatory data, and interviews with industry participants, and each report is reviewed by a senior analyst and fact-checked before publication.
Contact: Vectomat Insights | Email: sales@vectomatinsights.com | Website: www.vectomatinsights.com · +1 416-876-0312